The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Bioengineering virus‐like particles as vaccines
Abstract
Virus‐like particle (VLP) technology seeks to harness the optimally tuned immunostimulatory properties of natural viruses while omitting the infectious trait. VLPs that assemble from a single protein have been shown to be safe and highly efficacious in humans, and highly profitable. VLPs emerging from basic research possess varying levels of complexity and comprise single or multiple proteins, with or without a lipid membrane. Complex VLP assembly is traditionally orchestrated within cells using black‐box approaches, which are appropriate when knowledge and control over assembly are limited. Recovery challenges including those of adherent and intracellular contaminants must then be addressed. Recent commercial VLPs variously incorporate steps that include VLP in vitro assembly to address these problems robustly, but at the expense of process complexity. Increasing research activity and translation opportunity necessitate bioengineering advances and new bioprocessing modalities for efficient and cost‐effective production of VLPs. Emerging approaches are necessarily multi‐scale and multi‐disciplinary, encompassing diverse fields from computational design of molecules to new macro‐scale purification materials. In this review, we highlight historical and emerging VLP vaccine approaches. We overview approaches that seek to specifically engineer a desirable immune response through modular VLP design, and those that seek to improve bioprocess efficiency through inhibition of intracellular assembly to allow optimal use of existing purification technologies prior to cell‐free VLP assembly. Greater understanding of VLP assembly and increased interdisciplinary activity will see enormous progress in VLP technology over the coming decade, driven by clear translational opportunity. Biotechnol. Bioeng. 2014;111: 425–440. © 2013 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
The Many Roles of Computation in Drug Discovery
Jorgensen, W. L. (2004) · Science · doi:10.1126/science.1096361 · Cited by 1,554
Cryo-electron microscopy of viruses
Adrian, M., Dubochet, J., Lepault, J., & McDowall, A. W. (1984) · Nature · doi:10.1038/308032a0 · Cited by 1,342
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., & Schiller, J. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12180 · Cited by 1,110
Vaccine adjuvants: Current state and future trends
Petrovsky, N., & Aguilar, J. C. (2004) · Immunology & Cell Biology · doi:10.1111/j.0818-9641.2004.01272.x · Cited by 1,005
X-ray Crystallographic Structure of the Norwalk Virus Capsid
Prasad, B. V. V., Hardy, M. E., Dokland, T., Bella, J., Rossmann, M. G., & Estes, M. K. (1999) · Science · doi:10.1126/science.286.5438.287 · Cited by 946
Synthesis and assembly of hepatitis B virus surface antigen particles in yeast
Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G., & Hall, B. D. (1982) · Nature · doi:10.1038/298347a0 · Cited by 877
Virus-like particles in vaccine development
Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J., & Alves, P. M. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.115 · Cited by 845
Zhu, F.-C., Zhang, J., Zhang, X.-F., Zhou, C., Wang, Z.-Z., Huang, S.-J., Wang, H., Yang, C.-L., Jiang, H.-M., Cai, J.-P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61030-6 · Cited by 803
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
The Influence of Antigen Organization on B Cell Responsiveness
Bachmann, M. F., Rohrer, U. H., Kündig, T. M., Bürki, K., Hengartner, H., & Zinkernagel, R. M. (1993) · Science · doi:10.1126/science.8248784 · Cited by 717
The Crystal Structure of the Human Hepatitis B Virus Capsid
Wynne, S. A., Crowther, R. A., & Leslie, A. G. W. (1999) · Molecular Cell · doi:10.1016/s1097-2765(01)80009-5 · Cited by 667
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles
Kirnbauer, R., Taub, J. W., Greenstone, H. L., Roden, R. B. S., Dürst, M., Gissmann, L., Lowy, D. R., & Schiller, J. T. (1993) · Journal of Virology · doi:10.1128/jvi.67.12.6929-6936.1993 · Cited by 608
The atomic structure of the bluetongue virus core
Grimes, J. M., Burroughs, J. N., Gouet, P., Diprose, J. M., Malby, R., Ziéntara, S., Mertens, P. P. C., & Stuart, D. I. (1998) · Nature · doi:10.1038/26694 · Cited by 590
Kushnir, N., Streatfield, S. J., & Yusibov, V. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 587
Virus-like particles as immunogens
Noad, R., & Roy, P. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00208-7 · Cited by 581
Aguilar, J. C., & Rodríguez, E. G. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.111 · Cited by 494
Construction and Characterization of Virus-Like Particles: A Review
Zeltins, A. (2013) · Molecular Biotechnology · doi:10.1007/s12033-012-9598-4 · Cited by 478
The coming of age of virus-like particle vaccines
Jennings, G. T., & Bachmann, M. F. (2008) · bchm · doi:10.1515/bc.2008.064 · Cited by 369
VIPERdb2: an enhanced and web API enabled relational database for structural virology
Carrillo-Tripp, M., Shepherd, C. M., Borelli, I. A., Venkataraman, S., Lander, G., Natarajan, P., Johnson, J. E., Brooks, C. L., & Reddy, V. S. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn840 · Cited by 364
Cell-Specific Delivery of Diverse Cargos by Bacteriophage MS2 Virus-like Particles
Ashley, C. E., Carnes, E. C., Phillips, G. K., Durfee, P. N., Buley, M. D., Lino, C. A., Padilla, D. P., Phillips, B., Carter, M. B., Willman, C. L., et al. (2011) · ACS Nano · doi:10.1021/nn201397z · Cited by 350
Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein
Clarke, B. E., Newton, S. E., Carroll, A. R., Francis, M. J., Appleyard, G., Syred, A. D., Highfield, P. E., Rowlands, D. J., & Brown, F. (1987) · Nature · doi:10.1038/330381a0 · Cited by 333
Biological Gene Delivery Vehicles: Beyond Viral Vectors
Seow, Y., & Wood, M. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.41 · Cited by 327
Virus-like particles: flexible platforms for vaccine development
Chackerian, B. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.3.381 · Cited by 321
Self-assembly of purified polyomavirus capsid protein VP1
Salunke, D. M., Caspar, D. L. D., & Garcea, R. L. (1986) · Cell · doi:10.1016/0092-8674(86)90071-1 · Cited by 318
Chen, B. J., Leser, G. P., Morita, E., & Lamb, R. A. (2007) · Journal of Virology · doi:10.1128/jvi.00361-07 · Cited by 305
Bright, R. A., Carter, D. M., Daniluk, S., Toapanta, F. R., Ahmad, A., Gavrilov, V., Massare, M., Pushko, P., Mytle, N., Rowe, T., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.106 · Cited by 288
D’Aoust, M., Lavoie, P., Couture, M. M. ‐., Trépanier, S., Guay, J., Dargis, M., Mongrand, S., Landry, N., Ward, B. J., & Vézina, L. (2008) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2008.00384.x · Cited by 279
Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms
Stanley, M., Lowy, D. R., & Frazer, I. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.110 · Cited by 262
Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines
Bermúdez-Humarán, L. G., Kharrat, P., Chatel, J.-M., & Langella, P. (2011) · Microbial Cell Factories · doi:10.1186/1475-2859-10-s1-s4 · Cited by 243
Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design
Plummer, E. M., & Manchester, M. (2011) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.119 · Cited by 237
Computer-aided antibody design
Kuroda, D., Shirai, H., Jacobson, M. P., & Nakamura, H. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzs024 · Cited by 222
Protein delivery using engineered virus-like particles
Kaczmarczyk, S. J., Sitaraman, K., Young, H. A., Hughes, S. H., & Chatterjee, D. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101874108 · Cited by 219
Chung, Y.-C., Ho, M.-S., Wu, J.-C., Chen, W.-J., Huang, J.-H., Chou, S.-T., & Hu, Y.-C. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.01.058 · Cited by 214
Controlled Encapsulation of Multiple Proteins in Virus Capsids
Minten, I. J., Hendriks, L. J. A., Nolte, R. J. M., & Cornelissen, J. J. L. M. (2009) · Journal of the American Chemical Society · doi:10.1021/ja907843s · Cited by 204
RNA‐Directed Packaging of Enzymes within Virus‐like Particles
Fiedler, J. D., Brown, S. D., Lau, J. L., & Finn, M. G. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201005243 · Cited by 201
Giles, B. M., & Ross, T. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.100 · Cited by 199
French, T. J., & Roy, P. (1990) · Journal of Virology · doi:10.1128/jvi.64.4.1530-1536.1990 · Cited by 191
Chen, X. S., Casini, G., Harrison, S. C., & Garcea, R. L. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4464 · Cited by 185
Escherichia coli‐based cell‐free synthesis of virus‐like particles
Bundy, B. C., Franciszkowicz, M. J., & Swartz, J. R. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21716 · Cited by 179
Towards the preparative and large-scale precision manufacture of virus-like particles
Pattenden, L. K., Middelberg, A. P. J., Niebert, M., & Lipin, D. I. (2005) · Trends in Biotechnology · doi:10.1016/j.tibtech.2005.07.011 · Cited by 177
Self-citationPhase Diagram of Self-assembled Viral Capsid Protein Polymorphs
Lavelle, L., Gingery, M., Phillips, M., Gelbart, W. M., Knobler, C. M., Cadena-Nava, R. D., Vega-Acosta, J. R., Pinedo-Torres, L. A., & Ruiz-Garcia, J. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp8079765 · Cited by 170
O'Neil, A., Reichhardt, C., Johnson, B., Prevelige, P. E., & Douglas, T. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201102036 · Cited by 168
HPV6b virus like particles are potent immunogens without adjuvant in man
Zhang, L. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00351-5 · Cited by 163
Effective Chikungunya Virus-like Particle Vaccine Produced in Insect Cells
Metz, S. W., Gardner, J., Geertsema, C., Le, T. T., Goh, L., Vlak, J. M., Suhrbier, A., & Pijlman, G. P. (2013) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0002124 · Cited by 163
He, Y. O., Rappuoli, R., Groot, A. S. D., & Chen, R. T. (2010) · BioMed Research International · doi:10.1155/2010/218590 · Cited by 162
Zhao, X., Fox, J. M., Olson, N. H., Baker, T. S., & Young, M. J. (1995) · Virology · doi:10.1006/viro.1995.1108 · Cited by 161
Mach, H., Volkin, D. B., Troutman, R. D., Wang, B. E. I., Luo, Z., Jansen, K. U., & Shi, L. I. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20696 · Cited by 159
Park, S. B. (2012) · Nature · doi:10.1038/491021a · Cited by 156
Kato, S., Kobayashi, K., Inoue, K.-I., Kuramochi, M., Okada, T., Yaginuma, H., Morimoto, K., Shimada, T., Takada, M., & Kobayashi, K. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.179 · Cited by 156
Rational Engineering of Recombinant Picornavirus Capsids to Produce Safe, Protective Vaccine Antigen
Porta, C., Kotecha, A., Burman, A., Jackson, T., Ren, J., Loureiro, S., Jones, I. M., Fry, E. E., Stuart, D. I., & Charleston, B. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003255 · Cited by 156
Protein transduction from retroviral Gag precursors
Voelkel, C., Galla, M., Maetzig, T., Warlich, E., Kuehle, J., Zychlinski, D., Bode, J., Cantz, T., Schambach, A., & Baum, C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914517107 · Cited by 144
Quantitative Disassembly and Reassembly of Human Papillomavirus Type 11 Viruslike Particles In Vitro
McCarthy, M. P., White, W. I., Palmer‐Hill, F. J., Koenig, S., & Suzich, J. (1998) · Journal of Virology · doi:10.1128/jvi.72.1.32-41.1998 · Cited by 143
Immunization with a Pentameric L1 Fusion Protein Protects against Papillomavirus Infection
Yuan, H., Estes, P. A., Chen, Y., Newsome, J., Olcese, V. A., Garcea, R. L., & Schlegel, R. (2001) · Journal of Virology · doi:10.1128/jvi.75.17.7848-7853.2001 · Cited by 138
Osmolyte-Mediated Encapsulation of Proteins inside MS2 Viral Capsids
Glasgow, J. E., Capehart, S. L., Francis, M. B., & Tullman‐Ercek, D. (2012) · ACS Nano · doi:10.1021/nn302183h · Cited by 137
Deschuyteneer, M., Elouahabi, A., Plainchamp, D., et al. (2010) · Human Vaccines · doi:10.4161/hv.6.5.11023 · Cited by 132
Galarza, J. M., Latham, T. E., & Cupo, A. (2005) · Viral Immunology · doi:10.1089/vim.2005.18.244 · Cited by 129
Murawski, M. R., McGinnes, L. W., Finberg, R. W., Kurt‐Jones, E. A., Massare, M. J., Smith, G., Heaton, P. M., Fraire, A. E., & Morrison, T. G. (2009) · Journal of Virology · doi:10.1128/jvi.01709-09 · Cited by 127
Stabilization of human papillomavirus virus-like particles by non-ionic surfactants
Shi, L., Sanyal, G., Ni, A., et al. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20377 · Cited by 126
White, L., Hardy, M. E., & Estes, M. K. (1997) · Journal of Virology · doi:10.1128/jvi.71.10.8066-8072.1997 · Cited by 123
Human Papillomavirus Type 11 Recombinant L1 Capsomeres Induce Virus-Neutralizing Antibodies
Rose, R. C., White, W. I., Li, M., Suzich, J., Lane, C., & Garcea, R. L. (1998) · Journal of Virology · doi:10.1128/jvi.72.7.6151-6154.1998 · Cited by 120
Giles, B. M., Crevar, C. J., Carter, D. M., Bissel, S. J., Schultz‐Cherry, S., Wiley, C. A., & Ross, T. M. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis232 · Cited by 119
Atomic Force Microscopy in Imaging of Viruses and Virus-Infected Cells
Kuznetsov, Y., & McPherson, A. (2011) · Microbiology and Molecular Reviews · doi:10.1128/mmbr.00041-10 · Cited by 117
Pease, L. F., Lipin, D. I., Tsai, D., Zachariah, M. R., Lua, L. H. L., Tarlov, M. J., & Middelberg, A. P. J. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.22085 · Cited by 115
Self-citationEfficient disulfide bond formation in virus-like particles
Bundy, B. C., & Swartz, J. R. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.04.011 · Cited by 113
Zhao, Q., Modis, Y., High, K., Towne, V., Yuan, M., Wang, Y., Alexandroff, J., Brown, M. J., Carragher, B. O., Potter, C. S., et al. (2012) · Virology Journal · doi:10.1186/1743-422x-9-52 · Cited by 111
Incorporation of chimeric gag protein into retroviral particles
Weldon, R. A., Erdie, C. R., Oliver, M. G., & Wills, J. W. (1990) · Journal of Virology · doi:10.1128/jvi.64.9.4169-4179.1990 · Cited by 107
Multidimensional methods for the formulation of biopharmaceuticals and vaccines
Maddux, N. R., Joshi, S. B., Volkin, D. B., Ralston, J. P., & Middaugh, C. R. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22618 · Cited by 107
Prospects for an influenza vaccine that induces cross‐protective cytotoxic T lymphocytes
Brown, L. E., & Kelso, A. (2009) · Immunology and Cell Biology · doi:10.1038/icb.2009.16 · Cited by 103
McGinnes, L. W., Gravel, K. A., Finberg, R. W., Kurt‐Jones, E. A., Massare, M. J., Smith, G., Schmidt, M. R., & Morrison, T. G. (2010) · Journal of Virology · doi:10.1128/jvi.01861-10 · Cited by 103
Virus-like particles produced in plants as potential vaccines
Scotti, N., & Rybicki, E. P. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.147 · Cited by 103
Insect cells as a production platform of complex virus-like particles
Fernandes, F., Teixeira, A. P., Carinhas, N., Carrondo, M. J. T., & Alves, P. M. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.153 · Cited by 102
Cell-Specific Delivery of Bacteriophage-Encapsidated Ricin A Chain
Wu, M., Brown, W. L., & Stockley, P. G. (1995) · Bioconjugate Chemistry · doi:10.1021/bc00035a013 · Cited by 101
Abbing, A., Blaschke, U. K., Grein, S., Kretschmar, M., Stark, C. M. B., Thies, M., Walter, J. B., Weigand, M., Woith, D. C., Hess, J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313612200 · Cited by 100
Quantitative analysis of virus‐like particle size and distribution by field‐flow fractionation
Chuan, Y. P., Fan, Y., Lua, L. H. L., et al. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21710 · Cited by 96
Self-citationRamqvist, T., Andreasson, K., & Dalianis, T. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.7.997 · Cited by 94
Velasquez, L. S., Shira, S., Berta, A. N., Kilbourne, J. A., Medi, B. M., Tizard, I. R., Ni, Y., Arntzen, C. J., & Herbst‐Kralovetz, M. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.027 · Cited by 94
Expression, purification and characterization of enterovirus-71 virus-like particles
Chung, Y.-C., Huang, J., Lai, C., Sheng, H.-C., Shih, S.-R., Ho, M.-S., & Hu, Y.-C. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i6.921 · Cited by 93
Hillaire, M. L. B., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2011) · BioMed Research International · doi:10.1155/2011/939860 · Cited by 89
Li, H., Han, J., Qin, C., & Chen, R. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.019 · Cited by 87
Inoue, T., Kawano, M., Takahashi, R., Tsukamoto, H., Enomoto, T., Imai, T., Kataoka, K., & Handa, H. (2008) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2007.12.006 · Cited by 83
A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines
Middelberg, A. P. J., Rivera-Hernández, T., Wibowo, N., Lua, L. H. L., Fan, Y., Magor, G. W., Chang, C. J., Chuan, Y. P., Good, M. F., & Batzloff, M. R. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.075 · Cited by 83
Self-citationRasmussen, L. A., Battles, J. K.-L. K., Ennis, W. H., Nagashima, K., & Gonda, M. A. (1990) · Virology · doi:10.1016/0042-6822(90)90341-n · Cited by 83
Virus-like particles as universal influenza vaccines
Kang, S., Kim, M., & Compans, R. W. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.70 · Cited by 83
Peacey, M., Wilson, S., Baird, M. A., & Ward, V. K. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21518 · Cited by 82
Schneemann, A., Speir, J. A., Tan, G. S., Khayat, R., Ekiert, D. C., Matsuoka, Y., & Wilson, I. A. (2012) · Journal of Virology · doi:10.1128/jvi.01694-12 · Cited by 82
Giles, B. M., Bissel, S. J., DeAlmeida, D. R., Wiley, C. A., & Ross, T. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05533-11 · Cited by 81
Pushko, P., Pearce, M. B., Ahmad, A., Tretyakova, I., Smith, G., Belser, J. A., & Tumpey, T. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.068 · Cited by 79
Hepatitis B core–based virus–like particles to present heterologous epitopes
Roose, K., Baets, S. D., Schepens, B., & Saelens, X. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.150 · Cited by 78
Lin, T., Porta, C., Lomonossoff, G. P., & Johnson, J. E. (1996) · Folding and Design · doi:10.1016/s1359-0278(96)00030-2 · Cited by 77
Vaccine Potential of Nipah Virus-Like Particles
Walpita, P., Barr, J. A., Sherman, M. B., Basler, C. F., & Wang, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018437 · Cited by 76
Kosukegawa, A., Arisaka, F., Takayama, M., Yajima, H., Kaidow, A., & Handa, H. (1996) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(95)00184-0 · Cited by 75
Bräutigam, S., Snezhkov, E., & Bishop, D. H. L. (1993) · Virology · doi:10.1006/viro.1993.1067 · Cited by 72
Palomares, L. A., & Ramírez, O. T. (2009) · Biochemical Engineering Journal · doi:10.1016/j.bej.2009.02.006 · Cited by 70
Rational Design of a Stable, Freeze-Dried Virus-Like Particle-Based Vaccine Formulation
Lang, R., Winter, G., Vogt, L., Zürcher, A., Dorigo, B., & Schimmele, B. (2008) · Drug Development and Industrial Pharmacy · doi:10.1080/03639040802192806 · Cited by 67
Advances in Virus-Like Particle Vaccines for Filoviruses
Warfield, K. L., & Aman, M. J. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir346 · Cited by 66
Stability and assembly in vitro of bacteriophage PP7 virus-like particles
Caldeira, J. C., & Peabody, D. S. (2007) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-5-10 · Cited by 62
Microbial production of virus-like particle vaccine protein at gram-per-litre levels
Liew, M. W. O., Rajendran, A., & Middelberg, A. P. J. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.08.010 · Cited by 60
Self-citationPejawar‐Gaddy, S., Rajawat, Y. S., Hilioti, Z., Jia, X., Gaddy, D. F., Finn, O. J., Viscidi, R. P., & Bossis, I. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0895-0 · Cited by 59
Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris
Freivalds, J., Dišlers, A., Ose, V., Pumpens, P., Tārs, K., & Kazāks, A. (2010) · Protein Expression and Purification · doi:10.1016/j.pep.2010.09.010 · Cited by 55
Ibañez, L. I., Roose, K., Filette, M. D., Schotsaert, M., Sloovere, J. D., Roels, S., Pollard, C., Schepens, B., Grooten, J., Fiers, W. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059081 · Cited by 53
Keller, S. A., Bauer, M., Manolova, V., Muntwiler, S., Saudan, P., & Bachmann, M. F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901540 · Cited by 52
Modeling the competition between aggregation and self‐assembly during virus‐like particle processing
Ding, Y., Chuan, Y. P., He, L., & Middelberg, A. P. J. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22821 · Cited by 49
Self-citationLapelosa, M., Gallicchio, E., Arnold, G. F., Arnold, E., & Levy, R. M. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.089 · Cited by 48
Molecular Dynamics as a Tool in Rational Drug Design: Current Status and Some Major Applications
Galeazzi, R. (2009) · Current Computer - Aided Drug Design · doi:10.2174/157340909789577847 · Cited by 42
Mellado, M. C. M., Mena, J. A., Lopes, A., Ramı́rez, O. T., Carrondo, M. J. T., Palomares, L. A., & Alves, P. M. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22430 · Cited by 42
Freivalds, J., Dišlers, A., Ose, V., Skrastiņa, D., Cielēns, I., Pumpens, P., Sasnauskas, K., & Kazāks, A. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2005.11.013 · Cited by 40
Virus-like particle formulation optimization by miniaturized high-throughput screening
Mohr, J. C., Chuan, Y. P., Wu, Y., Lua, L. H. L., & Middelberg, A. P. J. (2013) · Methods · doi:10.1016/j.ymeth.2013.04.019 · Cited by 40
Self-citationDell, K., Koesters, R., Linnebacher, M., Klein, C., & Gissmann, L. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.11.060 · Cited by 38
Eriksson, M., Andreasson, K., Weidmann, J., Lundberg, K., Tegerstedt, K., Dalianis, T., & Ramqvist, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023828 · Cited by 38
全身性エリマトーデス患者のCD4 + Tリンパ球におけるIL-10およびIL13プロモーター領域の低メチル化
Ming, Z., Jinling, T., Gao, F., et al. (2010) · BioMed Research International · Cited by 37
Biophysical Characterization and Conformational Stability of Ebola and Marburg Virus-Like Particles
Hu, L., Trefethen, J. M., Zeng, Y., Yee, L., Ohtake, S., Lechuga‐Ballesteros, D., Warfield, K. L., Aman, M. J., Shulenin, S., Unfer, R. C., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22724 · Cited by 31
Joshi, H. V., Cheluvaraja, S., Somogyi, E., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.10.039 · Cited by 31
Anggraeni, M. R., Connors, N. K., Wu, Y., Chuan, Y. P., Lua, L. H. L., & Middelberg, A. P. J. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.06.087 · Cited by 30
Self-citationDesign of Hybrid Lipid/Retroviral-Like Particle Gene Delivery Vectors
Keswani, R. K., Pozdol, I. M., & Pack, D. W. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300561y · Cited by 30
Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines
Ahlers, J. D., & Belyakov, I. M. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.04.003 · Cited by 28
Low pH‐Triggered Model Drug Molecule Release from Virus‐Like Particles
Ohtake, N., Niikura, K., Suzuki, T., Nagakawa, K., Mikuni, S., Matsuo, Y., Kinjo, M., Sawa, H., & Ijiro, K. (2010) · ChemBioChem · doi:10.1002/cbic.201000094 · Cited by 25
Murata, Y., Lightfoote, P. M., Rose, R. C., & Walsh, E. E. (2009) · Virology Journal · doi:10.1186/1743-422x-6-81 · Cited by 25
SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier
Kawano, M., Matsui, M., & Handa, H. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.149 · Cited by 21
Guillén, G. E., Aguilar, J. C., Dueñas, S., Hermida, L., Guzmán, M., Pentón, E., Iglesias, E., Junco, J. A., Torréns, I., Lobaina, Y., et al. (2010) · Procedia in Vaccinology · doi:10.1016/j.provac.2010.07.004 · Cited by 20
Miao, Y., & Ortoleva, P. (2009) · Biopolymers · doi:10.1002/bip.21299 · Cited by 20
Zhang, L., Tang, R., Bai, S., Connors, N. K., Lua, L. H. L., Chuan, Y. P., Middelberg, A. P. J., & Sun, Y. P. (2013) · The Journal of Physical Chemistry B · doi:10.1021/jp311170w · Cited by 16
Self-citationDevelopments in virus-like particle-based vaccines for HIV
Buonaguro, L., Tagliamonte, M., Visciano, M. L., Tornesello, M. L., & Buonaguro, F. M. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.152 · Cited by 16
Nanosystem Self-Assembly Pathways Discovered via All-Atom Multiscale Analysis
Pankavich, S., & Ortoleva, P. (2012) · The Journal of Physical Chemistry B · doi:10.1021/jp210407e · Cited by 3
Cited by
Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414
Production and characterisation of stabilised PV-3 virus-like particles using Pichia pastoris
Sherry, L., Grehan, K., Swanson, J. J., Bahar, M. W., Porta, C., Fry, E. E., Stuart, D. I., Rowlands, D. J., & Stonehouse, N. J. (2022) · doi:10.1101/2022.09.16.508282 · Cited by 18
Structural and Biochemical Characterization of a Widespread Enterobacterial Peroxidase Encapsulin
(2025) · doi:10.1002/advs.202415827 · Cited by 7
Metadata
- Authors
- Lua, L. H. L., Connors, N. K., Sainsbury, F., Chuan, Y. P., Wibowo, N., & Middelberg, A. P. J.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2013-12-17
- Volume
- 111
- Issue
- 3
- Pages
- 425-440
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2146700406
- Cited by
- 355
- References
- 124
- FWCI
- 11.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.